Business Wire

New Airline CO2 Emissions Monitor From Cirium Reveals 40% Less Fuel Burnt From Flights Flown Globally In 2021

Share

Cirium, the aviation analytics company, today launched its Global Aircraft Emissions Monitor, providing a highly accurate measure of CO2 emissions and fuel consumption from flights flown globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005600/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium data shows the global flights tracked and fuel burn Jan-Nov 2021 versus 2019. (Graphic: Business Wire)

New insights from Cirium show that airlines have burnt 40% less fuel from flights in 2021 year-to-date compared to the same period in 2019.

The reduction in flight-produced carbon emissions is attributed to the drop in flights worldwide because of the dramatic impact that COVID-19 had on air travel. Flights tracked year-to-date are 29% down versus 2019.

The fuel burn has increased as domestic and international flights have started to return but not as much as expected compared to 2019—before the pandemic. The airlines have been flying their aircraft far fewer hours and prioritizing more efficient aircraft.

“To achieve the aggressive targets for aviation to reach net zero emissions by 2050, a thorough understanding is needed of all elements of an aircraft used for flights and the exact flight operations,” said Jeremy Bowen, CEO at Cirium.

“Cirium’s Global Aircraft Emissions Monitor boasts data of the highest quality and validity. The need for greater sustainability is clear and Cirium is committed to supporting the industry’s decision-making based on accurate carbon emissions tracking.”

The uniqueness of the product derives from the data, which is obtained from the widest and deepest data warehouse in the aviation industry. No other independent source can provide calculations based on the same blended data sets. The Monitor’s custom data calculations are based on hundreds of flight and aircraft variables for maximum accuracy. These variables include actual flight and taxi times, cabin configuration, aircraft operating empty weight, assumed cargo tonnage, aircraft/engine type, winglet equipage, aircraft age and more.

Tests conducted on the Global Aircraft Emissions Monitor have validated its accuracy in the order of 1%.

The Global Aircraft Emissions Monitor includes customized options for CO2 emissions and fuel consumption. It applies complete profiles of actual flights and aircraft, which are fused with block fuel burn models.

While aviation has reduced its emissions overall this year, travel is recovering, with Cirium forecasts projecting for global recovery to 2019 levels potentially by 2023. Cirium’s Fleet Forecast also predicts that based on the flight capacity of the increasing fleet to be in service by 2039, fuel burn may reach 485 million tons. This equates to 1,530 million tons of CO2 emissions, excluding any initiatives for sustainable aviation fuels (SAF) or offsetting.

Carbon emissions and fuel consumption from flights are increasingly becoming the centre focus for all airlines, airports aviation finance, aircraft manufacturers, air traffic management, government, and fuel providers.

The comprehensiveness of the Cirium Global Aircraft Emissions Monitor will enable organizations to track emissions as a measure of efficiency, understand aspects of total cost of ownership, understand the profile of a current operator, gain a better understanding of the climate impact, benchmark the competition, and create fuel demand models.

Find out more at https://cirium.com/EmissionsMonitor .

-End-

For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries please contact:
Mike Arnot, Juliett Alpha via cirium@juliettalpha.com
or the Cirium media team at media@cirium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye